- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02108418
Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers
A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution
- To evaluate the pharmacokinetics (PK) and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers.
- To evaluate the safety and tolerability of TG-2349 in healthy volunteers.
- To evaluate the ethnic differences in PK and safety between East Asian and Caucasian volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TG-2349 oral solution has been investigated in a phase I/IIa study (study number: TG-2349-01) in healthy volunteers and patients with chronic hepatitis C (CHC) infection. The study demonstrated that TG-2349 was safe and well-tolerated when given to healthy volunteers at single oral doses up to 800 mg, and at five-consecutive daily oral doses up to 600 mg. Co-administration of TG-2349 with food resulted in a significant increase in bioavailability, and therefore concomitant food intake with dosing is recommended.
To further advance the clinical development of TG-2349, a new capsule formulation was developed to replace the current TG-2349 oral solution. The objectives of this study (study number: TG-2349-02) are to evaluate the PK and relative bioavailability of TG-2349, given as a new capsule formulation and as the original formulation of oral solution, after a single oral dose of 400 mg under fed condition in healthy volunteers, and to evaluate the safety, tolerability, and ethnic differences of the TG-2349 capsule formulation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- WCCT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria at Screening
- East Asian or Caucasian subjects, male or female, and 18 to 40 years of age inclusive
- Body mass index (BMI) in the range of 19.0 to 30.0 kg/m2 and body weight ≥ 50 kg inclusive
- In general good physical and mental health status on the basis of a medical history review, medical evaluation including vital signs and physical examination, 12-lead ECG, and laboratory results at screening
- For females, one of the following criteria must be fulfilled:
(1)At least 1 year post menopausal, or (2)Surgically sterile, or (3)Willing to use a double-barrier method (intrauterine device [IUD] plus condom, spermicidal gel plus condom) of contraception from screening until 30 days after the last dose of study drug; 5.Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from screening until 30 days after the last dose of study drug 6.Willing to abstain from caffeine- or xanthine-containing beverages (including coffee and tea), alcohol, grapefruit juice, and Seville oranges during the stay-on-site period 7.Willing and able to provide written informed consent
Exclusion Criteria at Screening
- Positive serological test for IgM anti-HAV antibody, HbsAg, or anti-HCV antibody at screening
- Positive ELISA test for HIV-1 or HIV-2 at screening
- Any of the following abnormal laboratory values at screening: Hemoglobin (Hb) <12.0g/dL for women and <13.0g/dL for men, white blood cell count (WBC) <3,000 cells/mm3, absolute neutrophil count <1,500 cells/mm3, platelet count <100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 xULN, INR (International Normalized Ratios for prothrombin time) ≥1.5 xULN
- Any abnormal laboratory values that are considered clinically significant by the Investigator at screening
- QTcF greater than 450 msec for females and 430 msec for males at screening
- History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome
- History of seizures, epilepsy, cardiovascular, diabetes, or cancer (except basal cell carcinoma)
- History or family history of prolonged QT interval or family history of sudden cardiac death at a young age (< 30 years )
- History of drug allergy or hypersensitivity, especially to sulfa drugs
- History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use within 6 months prior to first dose of study drug administration
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or who have any history of suicide attempt or depression
- Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration
- Pregnant or breast-feeding
- Use of tobacco or nicotine-containing products within 30 days prior to first dose of study drug administration
- Use of concomitant medication, including herbal remedies and dietary supplements (except for paracetamol/acetaminophen, ibuprofen, and hormonal contraceptives) within 14 days prior to first dose of study drug administration
- Received any other investigational drug within 30 days prior to first dose of study drug administration
Exclusion Criteria at the First Admission
- Any of the following abnormal laboratory values at admission: Hb <12.0g/dL for women and <13.0g/dL for men, WBC <3,000 cells/mm3, absolute neutrophil count <1,500 cells/mm3, platelet count <100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 xULN, INR ≥ 1.5 xULN
- Any abnormal laboratory values that are considered clinically significant by the Investigator at admission
- Any clinically significant abnormality on 12-lead ECG or a QTcF greater than 450 msec for females and 430 msec for males at admission
- Positive urine drug screen or breath alcohol test at admission
- If female, positive serum pregnancy test at admission
- Acute illness within 2 weeks prior to dosing, unless approved by the Sponsor's Medical Monitor
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TG-2349 as the original formulation
400 mg, 2 syringes
|
single oral dose under fed condition
|
EXPERIMENTAL: TG-2349 as a new capsule formulation
400 mg, 4 capsules
|
single oral dose under fed condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary pharmacokinetic parameters: AUC0-t, AUC0-inf and Cmax
Time Frame: 120 hours after administration of study drug in each session
|
120 hours after administration of study drug in each session
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary pharmacokinetic parameters:Tmax, t1/2, CL/F, V/F and λz
Time Frame: 120 hours after administration of study drug in each session
|
120 hours after administration of study drug in each session
|
Urine pharmacokinetic parameters: Urine Ae%
Time Frame: 120 hours after administration of study drug in each session
|
120 hours after administration of study drug in each session
|
Stool pharmacokinetic parameters: Stool Ae%
Time Frame: 120 hours after administration of study drug in each session
|
120 hours after administration of study drug in each session
|
Safety parameters: Incidence and severity of AEs, changes from baseline in safety laboratory values, 12-lead ECG parameters, vital signs, and physical examination.
Time Frame: approximately 7 weeks
|
approximately 7 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicole Sims, DO, WCCT
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TG-2349-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on TG-2349 as the original formulation
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedCommunication | Adherence, PatientUnited States
-
University of Oslo School of PharmacyOslo University HospitalCompleted
-
University Medical Center GroningenRecruitingOral Cancer | Lymph Node MetastasesNetherlands
-
Shenzhen People's HospitalNot yet recruitingHypertensive EmergencyChina
-
Taiwan Liposome CompanyCompleted
-
University of PennsylvaniaRecruitingAlcoholism | Alcohol Use Disorder (AUD)United States